Junshi Biosciences
Innovative Drug Developer
2026Year7Month1Junshi Biosciences (688180.SH/01877.HK) issued a voluntary announcement disclosing that the Company has already6Month30On [date], signed the "License Agreement" with Jiangsu Wanbang Biopharmaceuticals, a wholly-owned subsidiary of Fosun Pharma, for its independently developed anti-IL-17AMonoclonal antibody Nivolumab (JS005) Exclusive out-licensing of all development, registration, manufacturing, and commercialization rights in the Greater China region, leveraging Fosun’s commercialization capabilities in the autoimmune field to accelerate product launch; this transaction features substantial financial consideration, with total potential proceeds reaching up to13.4RMB 100 million (including tax).
From the perspective of the scope of cooperative licensing, this agreement grants Jiangsu Wanbang Biopharmaceuticals two core licensing rights: first, an exclusive license for the development, registration, and commercialization of Ruokaoqibai Monoclonal Antibody in the Greater China region (covering mainland China, Hong Kong SAR, Macau SAR, and Taiwan Region); second, a joint exclusive license for the production of the product within this region. The agreement shall officially take effect on the date of signing by both parties, with its overall term remaining valid until Jiangsu Wanbang Biopharmaceuticals fulfills all payment obligations under the agreement. Separate term constraints are established for sales royalties; the royalty collection period for each region shall commence from the first commercial sale of the product in the local market and continue until15The agreement shall terminate at the latest of the following: the end of the annual sales period, the expiration of the core molecule’s patent, or the expiry of the local regulatory data protection exclusivity period. The agreement as a whole shall be governed by the laws of mainland China.
This timeBDThe financial terms of the transaction are clear, divided into a three-part payment system: First, Jiangsu Wanbang Biopharmaceuticals needs to pay2.15RMB 100 million (tax-inclusive) as a non-creditable, non-refundable down payment, to be paid upon the effectiveness of the agreement; secondly, establish tiered milestone payments, with a total cap11.25100 million yuan (including tax), with the highest development milestone1.8100 million yuan, payable upon achievement of R&D milestones such as product launch and indication expansion, with the highest sales milestone9.45hundred million yuan, to be disbursed in tiers based on the product’s annual sales volume; thirdly, Jiangsu Wanbang Biopharmaceuticals shall annually pay Junshi Biosciences a double-digit percentage of tiered sales royalties based on the net sales of the product in the Greater China region, thereby sharing in the long-term commercialization revenues of the product.
Taokibai monoclonal antibody is a self-developed specificIL-17AMonoclonal Antibodies, TargetsIL-17Ais a core pro-inflammatory factor driving autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis; the drug can bind with high affinityIL-17AHomodimers and heterodimers block the activation of inflammatory pathways, achieving relief of disease symptoms. Clinical data show that this product treats moderate-to-severe plaque psoriasisIIIProminent clinical manifestations during the registration phase,150mgDose Group No.16ZhouPASI 90Response Rate91%，52Weekly Long-term Follow-upPASI 100Response rate up to65%, with excellent efficacy and safety data;2025Year12month, the new drug application for its psoriasis indication (NDA) has been accepted by the National Medical Products Administration for the treatment of active ankylosing spondylitisIIPhase III clinical trials have also completed follow-up for all subjects, and the pipeline has potential for expansion into multiple indications, making it one of the leading domestic products in China.IL-17AInnovative Monoclonal Antibody Products.